<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma has filed the mandatory initial disclosure to both NSE and BSE as required under the SEBI circular dated October 19, 2023 for entities identified as Large Corporates. The company has confirmed that it does NOT fall under the Large Corporate category based on the applicable criteria. Key details disclosed include outstanding borrowings of Rs. 47.59 crore as on March 31, 2025, and a credit rating of CRISIL BBB+/Stable. The filing was signed by the CFO Deepak Sawant and Company Secretary Aditi Bhatt on April 30, 2025.
This is a routine compliance filing with no material impact on the stock or shareholders — it simply confirms the company is below the Large Corporate threshold and carries minimal debt of about Rs. 47.59 crore with an investment-grade credit rating.